Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

ProJenX

projenx.com ↗

Clinical Phase 1

Keywords: neurology neurodegenerative diseases Amyotrophic Lateral Sclerosis

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series A · $15M · announced Nov 2, 2023 Company release ↗
Source quote
- Nov 2, 2023 · Company release ↗
  “ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors NEW YORK”

Raises announced in these releases: $15M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Nov 2, 2023 Raise Series A · $15M source ↗
Feb 26, 2022 Trial start Phase 1: A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT05279755	A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS	Phase 1	Active, not recruiting	Feb 26, 2022	Jun 30, 2026 (estimated)